Literature DB >> 30521973

Loss of Enzyme Activity in Mutated B4GALNT1 Gene Products in Patients with Hereditary Spastic Paraplegia Results in Relatively Mild Neurological Disorders: Similarity with Phenotypes of B4galnt1 Knockout Mice.

Robiul H Bhuiyan1, Yuhsuke Ohmi2, Yuki Ohkawa1, Pu Zhang2, Maiko Takano2, Noboru Hashimoto3, Tetsuya Okajima3, Keiko Furukawa1, Koichi Furukawa4.   

Abstract

B4GALNT1 is an enzyme essential for the synthesis of complex gangliosides, whose absence leads to progressive neurodegeneration with aging in mice. Recently, eleven cases of hereditary spastic paraplegia with mutation in the coding region of B4GALNT1 were reported. However, changes in the enzymatic activity of their products have never been studied. We have constructed expression vectors for individual mutant cDNAs, and examined their activities by cell-free in vitro enzyme assays, and flow cytometry of cells transfected with their expression vectors. Among them, almost all mutant genes showed the complete loss of B4GALNT1 activity in both the in vitro enzyme assays and flow cytometry. Two mutants exceptionally showed weak activity. One of them, M4, had a mutation at amino acid 228 with a premature termination codon. Interestingly, the intensity of fluorescence of GM2 measured by flow cytometry was equivalent between the WT and M4 mutant, although the positive cell population was relatively small in M4. Western immunoblotting of cell lysates from transfectants with cDNA plasmids revealed 67-kDa bands except those containing premature termination codons or frame-shift mutation. Taken together with the clinical findings of patients, loss of enzyme activity may be responsible for the clinical features of hereditary spastic paraplegia, whereas the intensity of neurological disorders was relatively milder than expected. These clinical features of patients including those with male hypogonadism are very similar to the abnormal phenotypes detected in B4galnt1-deficient mice.
Copyright © 2018 IBRO. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  B4GALNT1; ganglioside; glycosphingolipid; golgi; hereditary spastic paraplegia; termination codon

Mesh:

Substances:

Year:  2018        PMID: 30521973     DOI: 10.1016/j.neuroscience.2018.11.034

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  11 in total

1.  Functional validation of novel variants in B4GALNT1 associated with early-onset complex hereditary spastic paraplegia with impaired ganglioside synthesis.

Authors:  Julian Emanuel Alecu; Yuhsuke Ohmi; Robiul H Bhuiyan; Kei-Ichiro Inamori; Takahiro Nitta; Afshin Saffari; Hellen Jumo; Marvin Ziegler; Claudio Melo de Gusmao; Nutan Sharma; Shiho Ohno; Noriyoshi Manabe; Yoshiki Yamaguchi; Mariko Kambe; Keiko Furukawa; Mustafa Sahin; Jin-Ichi Inokuchi; Koichi Furakawa; Darius Ebrahimi-Fakhari
Journal:  Am J Med Genet A       Date:  2022-07-01       Impact factor: 2.578

2.  Gangliosides in Neurodegenerative Diseases.

Authors:  Robert Ledeen; Suman Chowdhury
Journal:  Adv Neurobiol       Date:  2023

Review 3.  Elucidation of the enigma of glycosphingolipids in the regulation of inflammation and degeneration - Great progress over the last 70 years.

Authors:  Koichi Furukawa; Yuhsuke Ohmi; Yuji Kondo; Robiul H Bhuiyan; Orie Tajima; Pu Zhang; Yuki Ohkawa; Keiko Furukawa
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2019       Impact factor: 3.493

Review 4.  Novel Molecular Mechanisms of Gangliosides in the Nervous System Elucidated by Genetic Engineering.

Authors:  Koichi Furukawa; Yuhsuke Ohmi; Farhana Yesmin; Orie Tajima; Yuji Kondo; Pu Zhang; Noboru Hashimoto; Yuki Ohkawa; Robiul H Bhuiyan; Keiko Furukawa
Journal:  Int J Mol Sci       Date:  2020-03-11       Impact factor: 5.923

5.  Subnormal GM1 in PBMCs: Promise for Early Diagnosis of Parkinson's Disease?

Authors:  Samar K Alselehdar; Monami Chakraborty; Suman Chowdhury; Roy N Alcalay; Matthew Surface; Robert Ledeen
Journal:  Int J Mol Sci       Date:  2021-10-26       Impact factor: 5.923

Review 6.  Glycosphingolipid metabolism and its role in ageing and Parkinson's disease.

Authors:  Kerri-Lee Wallom; María E Fernández-Suárez; David A Priestman; Danielle Te Vruchte; Mylene Huebecker; Penelope J Hallett; Ole Isacson; Frances M Platt
Journal:  Glycoconj J       Date:  2021-11-10       Impact factor: 2.916

7.  Systemic deficiency of GM1 ganglioside in Parkinson's disease tissues and its relation to the disease etiology.

Authors:  Robert Ledeen; Suman Chowdhury; Zi-Hua Lu; Monami Chakraborty; Gusheng Wu
Journal:  Glycoconj J       Date:  2022-01-01       Impact factor: 2.916

Review 8.  Metabolism of Glycosphingolipids and Their Role in the Pathophysiology of Lysosomal Storage Disorders.

Authors:  Alex E Ryckman; Inka Brockhausen; Jagdeep S Walia
Journal:  Int J Mol Sci       Date:  2020-09-19       Impact factor: 5.923

Review 9.  Roles of Gangliosides in Hypothalamic Control of Energy Balance: New Insights.

Authors:  Kei-Ichiro Inamori; Jin-Ichi Inokuchi
Journal:  Int J Mol Sci       Date:  2020-07-28       Impact factor: 5.923

10.  B4GALNT1 enhances cell proliferation and growth in oral squamous cell carcinoma via p38 and JNK MAPK pathway.

Authors:  Shaohong Jing; Zhaoming Deng; Lizhong Liang; Jun Liang
Journal:  Transl Cancer Res       Date:  2020-04       Impact factor: 1.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.